Literature DB >> 19605786

Neutralization of vascular endothelial growth factor antiangiogenic isoforms is more effective than treatment with proangiogenic isoforms in stimulating vascular development and follicle progression in the perinatal rat ovary.

Robin A Artac1, Renee M McFee, Robyn A Longfellow Smith, Michelle M Baltes-Breitwisch, Debra T Clopton, Andrea S Cupp.   

Abstract

Inhibition of vascular endothelial growth factor A (VEGFA) signal transduction arrests vascular and follicle development. Because antiangiogenic VEGFA isoforms are proposed to block proangiogenic VEGFA isoforms from binding to their receptors, we hypothesized that proangiogenic isoforms promote and antiangiogenic isoforms inhibit these processes. The antiangiogenic isoforms Vegfa_165b and Vegfa_189b were amplified and sequenced from rat ovaries. The Vegfa_165b sequence was 90% homologous to human VEGFA_165B. Quantitative RT-PCR determined that Vegfa_165b mRNA was more abundant around Embryonic Day 18, but Vegfa_189b lacked a distinct pattern of abundance. Antiangiogenic VEGFA isoforms were localized to pregranulosa and granulosa cells of all follicle stages and to theca cells of advanced-stage follicles. To determine the effects of VEGFA isoforms in developing ovaries, Postnatal Day 3/4 rat ovaries were cultured with VEGFA_164 or an antibody to antiangiogenic isoforms (anti-VEGFAxxxB). Treatment with 50 ng/ml of VEGFA_164 resulted in a 93% increase in vascular density (P < 0.01), and treated ovaries were composed of fewer primordial follicles (stage 0) and more developing follicles (stages 1-4) than controls (P < 0.04). Ovaries treated with 5 ng/ml of VEGFAxxxB antibody had a 93% increase in vascular density (P < 0.02), with fewer primordial and early primary follicles (stage 1) and more primary, transitional, and secondary follicles (stages 2, 3, and 4, respectively) compared with controls (P < 0.005). We conclude that neutralization of antiangiogenic VEGFA isoforms may be a more effective mechanism of enhancing vascular and follicular development in perinatal rat ovaries than treatment with the proangiogenic isoform VEGFA_164.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19605786      PMCID: PMC2770023          DOI: 10.1095/biolreprod.109.078097

Source DB:  PubMed          Journal:  Biol Reprod        ISSN: 0006-3363            Impact factor:   4.285


  29 in total

1.  Oocyte-specific deletion of Pten causes premature activation of the primordial follicle pool.

Authors:  Pradeep Reddy; Lian Liu; Deepak Adhikari; Krishna Jagarlamudi; Singareddy Rajareddy; Yan Shen; Chun Du; Wenli Tang; Tuula Hämäläinen; Stanford L Peng; Zi-Jian Lan; Austin J Cooney; Ilpo Huhtaniemi; Kui Liu
Journal:  Science       Date:  2008-02-01       Impact factor: 47.728

2.  VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice.

Authors:  O Konopatskaya; A J Churchill; S J Harper; David O Bates; T A Gardiner
Journal:  Mol Vis       Date:  2006-05-26       Impact factor: 2.367

Review 3.  Cellular interactions that control primordial follicle development and folliculogenesis.

Authors:  E Nilsson; M K Skinner
Journal:  J Soc Gynecol Investig       Date:  2001 Jan-Feb

4.  Induction of angiogenesis by implantation of encapsulated primary myoblasts expressing vascular endothelial growth factor.

Authors:  M L Springer; G Hortelano; D M Bouley; J Wong; P E Kraft; H M Blau
Journal:  J Gene Med       Date:  2000 Jul-Aug       Impact factor: 4.565

5.  Isoforms of vascular endothelial growth factor act in a coordinate fashion To recruit and expand tumor vasculature.

Authors:  J Grunstein; J J Masbad; R Hickey; F Giordano; R S Johnson
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

6.  The endogenous anti-angiogenic family of splice variants of VEGF, VEGFxxxb, are down-regulated in pre-eclamptic placentae at term.

Authors:  David O Bates; Philip P MacMillan; Joseph G Manjaly; Yan Qiu; Sarah J Hudson; Heather S Bevan; Alyson J Hunter; Peter W Soothill; Michael Read; Lucy F Donaldson; Steven J Harper
Journal:  Clin Sci (Lond)       Date:  2006-05       Impact factor: 6.124

7.  VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma.

Authors:  David O Bates; Tai-Gen Cui; Joanne M Doughty; Matthias Winkler; Marto Sugiono; Jacqueline D Shields; Danielle Peat; David Gillatt; Steven J Harper
Journal:  Cancer Res       Date:  2002-07-15       Impact factor: 12.701

8.  Inhibition of vascular endothelial growth factor receptor signal transduction blocks follicle progression but does not necessarily disrupt vascular development in perinatal rat ovaries.

Authors:  Renee M McFee; Robin A Artac; Ryann M McFee; Debra T Clopton; Robyn A Longfellow Smith; Timothy G Rozell; Andrea S Cupp
Journal:  Biol Reprod       Date:  2009-07-15       Impact factor: 4.285

9.  Mouse ovarian germ cell cysts undergo programmed breakdown to form primordial follicles.

Authors:  M E Pepling; A C Spradling
Journal:  Dev Biol       Date:  2001-06-15       Impact factor: 3.582

Review 10.  VEGF-A splicing: the key to anti-angiogenic therapeutics?

Authors:  Steven J Harper; David O Bates
Journal:  Nat Rev Cancer       Date:  2008-10-16       Impact factor: 60.716

View more
  19 in total

1.  Neutralization of vascular endothelial growth factor antiangiogenic isoforms or administration of proangiogenic isoforms stimulates vascular development in the rat testis.

Authors:  Michelle M Baltes-Breitwisch; Robin A Artac; Rebecca C Bott; Renee M McFee; Jill G Kerl; Debra T Clopton; Andrea S Cupp
Journal:  Reproduction       Date:  2010-05-10       Impact factor: 3.906

Review 2.  Kinase inhibitors: the road ahead.

Authors:  Fleur M Ferguson; Nathanael S Gray
Journal:  Nat Rev Drug Discov       Date:  2018-03-16       Impact factor: 84.694

3.  Transcriptomic diversification of developing cumulus and mural granulosa cells in mouse ovarian follicles.

Authors:  Karen Wigglesworth; Kyung-Bon Lee; Chihiro Emori; Koji Sugiura; John J Eppig
Journal:  Biol Reprod       Date:  2014-11-05       Impact factor: 4.285

4.  The VEGF165b "ICE-o-form" puts a chill on the VEGF story.

Authors:  Ayotunde O Dokun; Brian H Annex
Journal:  Circ Res       Date:  2011-07-22       Impact factor: 17.367

Review 5.  The role of VEGF 165b in pathophysiology.

Authors:  Maria Peiris-Pagès
Journal:  Cell Adh Migr       Date:  2012-10-17       Impact factor: 3.405

Review 6.  Vascular endothelial growth factor A: just one of multiple mechanisms for sex-specific vascular development within the testis?

Authors:  Kevin M Sargent; Renee M McFee; Renata Spuri Gomes; Andrea S Cupp
Journal:  J Endocrinol       Date:  2015-10-15       Impact factor: 4.286

7.  Loss of vascular endothelial growth factor A (VEGFA) isoforms in the testes of male mice causes subfertility, reduces sperm numbers, and alters expression of genes that regulate undifferentiated spermatogonia.

Authors:  Ningxia Lu; Kevin M Sargent; Debra T Clopton; William E Pohlmeier; Vanessa M Brauer; Renee M McFee; John S Weber; Napoleone Ferrara; David W Silversides; Andrea S Cupp
Journal:  Endocrinology       Date:  2013-10-29       Impact factor: 4.736

8.  VEGF(121)b, a new member of the VEGF(xxx)b family of VEGF-A splice isoforms, inhibits neovascularisation and tumour growth in vivo.

Authors:  E S Rennel; A H R Varey; A J Churchill; E R Wheatley; L Stewart; S Mather; D O Bates; S J Harper
Journal:  Br J Cancer       Date:  2009-08-25       Impact factor: 7.640

9.  The anti-angiogenic isoforms of VEGF in health and disease.

Authors:  Yan Qiu; Coralie Hoareau-Aveilla; Sebastian Oltean; Steven J Harper; David O Bates
Journal:  Biochem Soc Trans       Date:  2009-12       Impact factor: 5.407

Review 10.  Molecular diversity of VEGF-A as a regulator of its biological activity.

Authors:  Jeanette Woolard; Heather S Bevan; Steven J Harper; David O Bates
Journal:  Microcirculation       Date:  2009-06-01       Impact factor: 2.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.